Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absence, accessibility, actinic, acuminata, acuminate, add, arbitration, Atlantic, augmentation, balding, bankrupt, Belotero, bench, bid, bidding, carrier, Chapter, chronological, clotting, condyloma, contemplated, counter, Ct, default, Dist, diversification, driven, expedited, floor, genital, goal, Graceway, headcount, hereunder, imiquimod, immunocompetent, improperly, India, isde, jury, LAVIVTM, Leo, lip, maximize, meantime, Memorandum, memorialize, MetroGel, mouth, noncontributory, nose, novo, outbreak, overhead, palpable, panel, percentile, perianal, postpone, premium, principle, print, pump, rabbi, reassigned, remote, resignation, Resiquimod, respiratory, revaluation, Road, run, Sanofi, scalp, SERP, signatory, Solta, solvency, submucosal, summer, surrender, tier, twenty, unamortized, unnecessary, unplanned, Valeant, visible, Watson, withdrew, WL, women, wrapper, ZYCLARA
Removed:
accretion, Alternatively, andRESTYLANE, avian, Baddour, Baldini, BancBoston, begun, Bioglan, bring, carryforward, ceased, Clemente, comparably, contingency, Contingently, disposal, DYNACIN, EITF, Emmett, enterprise, ERP, Exorex, Flynn, Furman, Hanson, hazard, identifying, implementing, IMX, Inamed, indefinite, influenza, inquiry, introduced, irrevocable, Likewise, loan, Lotion, Masterpiece, merit, morbidity, mortality, MPC, mutation, nation, Norwest, Parallel, persist, pose, premarketing, Raymond, RELOXIN, remediate, remediated, retrospective, Robert, rosacea, sculpting, Seattle, Selz, SOLODYN®in, SUBQTM, sulfacetamide, sulfur, threatening, Tradename, treated, TRIAZ®branded, unenforceable, uninterrupted, vacating, Voting, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 12 Computation of Ratios of Earnings to Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14(A) and Rule 15D
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14(A) and Rule 15D
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Related press release
Medicis Pharmaceutical similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 33-88590, 333-11419, 333-33647, 333-101467, 333-126785, 333-135675, 333-144334, 333-159714 and 333-176185), and in the Registration Statement (Form S-3 No. 333-97207) of Medicis Pharmaceutical Corporation of our reports dated February 27, 2012, with respect to the consolidated financial statements and schedule of Medicis Pharmaceutical Corporation and the effectiveness of internal control over financial reporting of Medicis Pharmaceutical Corporation, included in its Annual Report (Form 10-K) for the year ended December 31, 2011.
/s/ Ernst & Young LLP
Phoenix, Arizona
February 27, 2012